Sildenafil for erectile dysfunction in the middle east: Observational analysis of patients with diabetes and/or hypertension treated in the clinical practice setting

Journal of International Medical Research

Volumn 39, Issue 2, 2011, Pages 558-568

  El Sakka, A I ^a,b   Anis, T ^c   Khadr, N ^d   Ismail, T A ^e   Hegazy, A M ^e   Fekry, O ^e   Youseif, E ^e  

^a Suez Canal University Faculty of Medicine   (Egypt)

^b AL NOOR SPECIALIST HOSPITAL   (Saudi Arabia)

^c CAIRO UNIVERSITY   (Egypt)

^d Khadr Cardiology Clinic   (United Arab Emirates)

^e PFIZER INC   (United States)

Author keywords

Effectiveness; Erectile dysfunction; Hypertension; Sildenafil citrate; Tolerability; Type 2 diabetes

Indexed keywords

SILDENAFIL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; FLUSHING; HEADACHE; HEART RATE; HUMAN; HYPERTENSION; INTERNATIONAL INDEX OF ERECTILE FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE EAST; NON INSULIN DEPENDENT DIABETES MELLITUS; NOSE CONGESTION; OBSERVATIONAL STUDY; OPEN STUDY; OUTPATIENT; SEXUAL BEHAVIOR; SEXUAL INTERCOURSE; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

EID: 79955647447     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001103900225     Document Type: Article

References (36)

1. El-Sakka AI, Tayeb KA: Erectile dysfunction risk factors in noninsulin dependent diabetic Saudi patients. J Urol 2003; 169: 1043-1047.
2. El-Sakka AI: Characteristics of erectile dysfunction in Saudi patients. Int J Impot Res 2004; 16: 13-20.
3. Safarinejad MR: Prevalence and risk factors for erectile dysfunction in a population-based study in Iran. Int J Impot Res 2003; 15: 246-252.
4. Khatib OMN: National diabetes programmes in the Arab world. In: Diabetes in the Arab World (Lakhdar A, Gill GV eds). Cambridge: FSG Communications, 2005; pp 285-295.
5. Al-Nozha MM, Al-Maatouq MA, Al-Mazrou YY, et al: Diabetes mellitus in Saudi Arabia. Saudi Med J 2004; 25: 1603-1610.
6. Mubarak FM, Froelicher ES, Jaddou HY, et al: Hypertension among 1000 patients with type 2 diabetes attending a national diabetes center in Jordan. Ann Saudi Med 2008; 26: 346-351.
7. Aytac IA, McKinlay JB, Krane RJ: The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999; 84: 50-56.
8. Nehra A: Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions. Mayo Clin Proc 2009; 84: 139-148.
9. Motlagh B, O'Donnell M, Yusuf S: Prevalence of cardiovascular risk factors in the Middle East: a systematic review. Eur J Cardiovasc Prev Rehabil 2009; 16: 268-280.
10. El-Sakka AI, Morsy AM, Fagih BI, et al: Coronary artery risk factors in patients with erectile dysfunction. J Urol 2004; 172: 251-254.
11. Hodoǧlugil U, Mahley RW: Smoking and obesity make a bad problem worse: genetics and lifestyle affect high density lipoprotein levels in Turks. Anadolu Kardiyol Derg 2006; 6: 60-67.
12. Sánchez-Cruz JJ, Cabrera-León A, Martín-Morales A, et al: Male erectile dysfunction and health-related quality of life. Eur Urol 2003; 44: 245-253.
13. Fugl-Meyer AR, Lodnert G, Branholm IB, et al: On life satisfaction in male erectile dysfunction. Int J Impot Res 1997; 9: 141-148.
14. Burls A, Gold L, Clark W: Systematic review of randomised controlled trials of sildenafil (Viagra) in the treatment of male erectile dysfunction. Br J Gen Pract 2001; 51: 1004-1012.
15. Osterloh IH, Collins M, Wicker P, et al: Sildenafil citrate (VIAGRA): overall safety profile in 18 double-blind, placebo controlled, clinical trials. Int J Clin Pract Suppl 1999; 102: 3-5.
16. Levinson IP, Khalaf IM, Shaeer KZ, et al: Efficacy and safety of sildenafil citrate (Viagra®) for the treatment of erectile dysfunction in men in Egypt and South Africa. Int J Impot Res 2003; 15(suppl 1): S25-S29.
17. Safarinejad MR: Oral sildenafil in the treatment of erectile dysfunction in diabetic men: a randomized double-blind and placebocontrolled study. J Diabetes Complications 2004; 18: 205-210.
18. Aversa A, Vitale C, Volterrani M, et al: Chronic administration of sildenafil improves markers of endothelial function in men with type 2 diabetes. Diabet Med 2008; 25: 37-44.
19. Shamloul R, Ghanem H, Abou-zeid A: Validity of the Arabic version of the sexual health inventory for men among Egyptians. Int J Impot Res 2004; 16: 452-455.
20. Rosen RC, Cappelleri JC, Smith MD, et al: Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999; 11: 319-326.
21. Hanson-Divers C, Jackson SE, Lue TF, et al: Health outcomes variables important to patients in the treatment of erectile dysfunction. J Urol 1998; 159: 1541-1547.
22. Goldstein I, Mulhall JP, Bushmakin AG, et al: The erection hardness score and its relationship to successful sexual intercourse. J Sex Med 2008; 5: 2374-2380.
23. Tsertsvadze A, Fink HA, Yazdi F, et al: Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. Ann Intern Med 2009; 151: 650-661.
24. Lydiard RB, Perera P, Batzar E, et al: From the bench to the trench: a comparison of sertraline treatment of major depression in clinical and research patient samples. Prim Care Companion J Clin Psychiatry 1999; 1: 154-162.
25. Blanco C, Olfson M, Okuda M, et al: Generalizability of clinical trials for alcohol dependence to community samples. Drug Alcohol Depend 2008; 98: 123-128.
26. Tsertsvadze A, Yazdi F, Fink HA, et al: Oral sildenafil citrate (Viagra) for erectile dysfunction: a systematic review and metaanalysis of harms. Urology 2009; 74: 831-836.
27. Knol MJ, Twisk JW, Beekman AT, et al: Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis. Diabetologia 2006; 49: 837-845.
28. Mezuk B, Eaton WW, Albrecht S, et al: Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care 2008; 31: 2383-2390.
29. Nouwen A, Winkley K, Twisk J, et al. for the European Depression in Diabetes (EDID) Research Consortium: Type 2 diabetes mellitus as a risk factor for the onset of depression: a systematic review and meta-analysis. Diabetologia 2010 53: 2480-2486.
30. Okamura F, Tashiro A, Utumi A, et al: Insulin resistance in patients with depression and its changes during the clinical course of depression: minimal model analysis. Metabolism 2000; 49: 1255-1260.
31. Carnethon MR, Kinder LS, Fair JM, et al: Symptoms of depression as a risk factor for incident diabetes: findings from the National Health and Nutrition Examination Epidemiologic Follow-up Study, 1971-1992. Am J Epidemiol 2003; 158: 416-423.
32. Pan A, Ye X, Franco OH, et al: Insulin resistance and depressive symptoms in middle-aged and elderly Chinese: findings from the Nutrition and Health of Aging Population in China Study. J Affect Disord 2008; 109: 75-82.
33. Wagner J, Allen NA, Swalley LM, et al: Depression, depression treatment, and insulin sensitivity in adults at risk for type 2 diabetes. Diabetes Res Clin Pract 2009; 86: 96-103.
34. Flather M, Delahunty N, Collinson J: Generalizing results of randomized trials to clinical practice: reliability and cautions. Clin Trials 2006; 3: 508-512.
35. Tunis SR, Stryer DB, Clancy CM: Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003; 290: 1624-1632.
36. Treweek S, Zwarenstein M: Making trials matter: pragmatic and explanatory trials and the problem of applicability. Trials 2009; 10: 37.